Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier) [Corrigendum]
Authors Casadei-Gardini A, Montagnani F, Casadei C, Arcadipane F, Andrikou K, Aloi D, Prete AA, Zampino MG, Argentiero A, Pugliese G, Martini S, Iorio GC, Scartozzi M, Mistrangelo M, Fornaro L, Cassoni P, Marisi G, Dell'Acqua V, Ravenda PS, Lonardi S, Silvestris N, De Bari B, Ricardi U, Cascinu S, Franco P
Received 9 May 2019
Accepted for publication 9 May 2019
Published 25 June 2019 Volume 2019:11 Pages 5123—5124
Casadei-Gardini A, Montagnani F, Casadei C, et al. Cancer Manag Res. 2019;11:3631–3642.
The authors have advised that the affiliations are not correct in the published paper (page 3631). They have provided revised author and affiliations lists, as follows, and confirm that the modifications do not alter their conflicts of interest status in regard to this work.
Andrea Casadei-Gardini,1,2 Francesco Montagnani,3 Chiara Casadei,1 Francesca Arcadipane,4 Kalliopi Andrikou,2 Deborah Aloi,5 Alessandra Anna Prete,6 Maria Giulia Zampino,7 Antonella Argentiero,8 Giuseppe Pugliese,2 Stefania Martini,4 Giuseppe Carlo Iorio,4 Mario Scartozzi,9 Massimiliano Mistrangelo,10 Lorenzo Fornaro,11 Paola Cassoni,12 Giorgia Marisi,13 Veronica Dell’Acqua,14 Paola Simona Ravenda,7 Sara Lonardi,6 Nicola Silvestris,8 Berardino De Bari,5 Umberto Ricardi,4 Stefano Cascinu,2 Pierfrancesco Franco4
1Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy; 2Department of Hematology and Oncology, University of Modena and Reggio Emilia, Modena, Italy; 3Oncology Department, SOC Oncology, ASL (Health Local Authority), Biella, Italy; 4Department of Oncology, Radiation Oncology, University of Turin, Turin, Italy; 5Radiation Oncology Department, Centre Hospitalier Régional Universitaire “Jean Minjoz”, Besançon Cedex, France; 6Unit of Medical Oncology 1, Department of Clinical and Experimental Oncology, Istituto Oncologico Veneto, IRCCS, Padua, Italy; 7Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, IRCCS, Milan, Italy; 8Medical Oncology Unit, Cancer Institute Giovanni Paolo II, Bari, Italy; 9Department of Medical Oncology, University of Cagliari, Cagliari, Italy; 10Department of Surgical Sciences, University of Turin, Turin, Italy; 11Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana University, Pisa, Italy; 12Department of Medical Sciences, Pathology Unit, University of Turin, Turin, Italy; 13Biosciences Laboratory, Istituto Scientifico Romagnolo per Lo Studio e La Cura Dei Tumori (IRST) IRCCS, Meldola, Italy; 14Department of Radiotherapy, IRCCS, European Institute of Oncology, Milan, Italy
Read the original article
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]